Researchers in Switzerland have conducted the first systematic study that demonstrated that even small variations in a person’s genome can disrupt the therapeutic effects of monoclonal antibodies. “We ...

Dec 2 (Reuters) - The U.S. Food and Drug Administration on Tuesday issued new draft guidance on reducing the use of lab monkeys in preclinical toxicity studies for certain monoclonal antibodies. The ...

The FDA has released a plan to stop or reduce the use of primates for testing the safety of certain monoclonal antibodies (mAbs), the latest expansion of the regulator’s efforts to eliminate animal ...

Respiratory syncytial virus (RSV) is a common respiratory virus which usually causes mild, cold-like symptoms during the respiratory virus season. However, especially among young infants under six ...

Publication includes complete data for all participants (n=39) up to week 72, further demonstrating durable and tolerable expression of DMAbs Effective target binding and confirmed functional activity ...

Monoclonal antibodies (mAbs) have revolutionized modern medicine, offering precision therapies for cancer, autoimmune disorders, infectious diseases, and numerous other advantages. The global mAb ...

Malaria remains one of the leading causes of death among children in sub-Saharan Africa, claiming more than 600,000 lives each year worldwide with limited efficacy in currently available treatments ...

The FDA on Friday revoked the emergency use authorizations (EUAs) of four monoclonal antibodies for COVID-19. The four drugs -- bebtelovimab, sotrovimab, casirivimab ...

A team from the Microbiology Department at the Icahn School of Medicine at Mount Sinai has discovered three powerful monoclonal antibodies from a person who had previously been infected with mpox ...

Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...

Approximately 40% of the European population is allergic to pollen, and their symptoms cause the estimated loss of 100 million school and work days every year. Traditional treatment is ...

B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...